2026-10-25
Medtronic clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 29,813 +0.55%
S&P 7,744 +0.28%
GOLD $4,037 −0.37%
BTC $79,765 −1.85%
VIX 17.26 +2.07%
latest tape · as of 08:02 UTC
The Screen · Healthcare · Medical Devices
Medtronic
MDT · a US exchange · USD · Market cap $122.1B · 95,000 employees
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.
Not yet scored95.41 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 6 days ago
Screened 2026-10-23 · the tape above runs as of 08:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price95.41 USD at the 23 Oct 2026 close
- Our ratingFair value, current read markup
- Ethical screenNot yet scored
- OptionsOpen interest leans to puts (put/call 1.36)
- Last reviewed23 Oct 2026 (6 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 95.41 against the desk's fair-value range, base estimate 121.00, over the last year.
- Trend Markup
- Insiders insiders sold, $1,000,320, latest filing 2026-10-15
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 1.36, read 2026-10-28
- Ethical screen not yet scored
Price95.41 USD
Fair value121.00
Ethical score83.0/100
RatingFAIR VALUE
Our investment reviews on this name
2026-10-21Read Markup95.450.0% to today Distribution gives way to Markup after an 8% rise in 3 weeks
2026-10-02Read Distribution88.64+7.6% to today Markup gives way to Distribution after a 7% rise in 8 weeks
2026-08-05Read Markup83.21+14.7% to today ✓Distribution gives way to Markup
2026-07-02Read Distribution81.67+16.8% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markup label.
Medtronic holds its Markup at $95.41. Consolidating, no directional conviction, held for 52 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 52 days |
| Price at the screen | $95.41 |
| Valuation | 23.45 trailing · 14.89 forward price to earnings |
| Values screen | Not scored · score 83.0 |
| Beta | 0.57 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 31.10% | Below 33% | Interest-bearing debt is just 31.1% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 7.36% | Below 33% | Cash held in interest-bearing accounts and securities is 7.4% of assets, under the one-third limit. | Pass |
| Receivables | 9.53% | Below 49% | Money owed to the company is 9.5% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Medtronic clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Medtronic clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 31%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads FAIR VALUE: it trades at roughly a 27% discount to our $121.00 fair value, narrow competitive moat, 13.70% revenue growth.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 26.8% margin of safety to the base estimate.
Third-party analyst targets: 25 covering, consensus Buy. The average target sits +11% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsMedtronic's Life-Saving Tech, Undervalued Potential
Picturing a remote village in Ireland, a pacemaker from Medtronic could mean the difference between life and death. This is no exaggeration, as Medtronic's device-based medical therapies span from implantable pacemakers to advanced surgical equipment, proving essential in healthcare systems globally. Why it stands out is evident in its fair value of $120.51 against its current price of $92.30, presenting a significant margin of safety of +31%, with a forward P/E of 14.4x, reflecting a market undervaluation of this ethically scrutinized and cleared medical titan.
The numbers tell a compelling story: a 10% revenue growth and a 13% profit margin are solid, though the ROE of 10% and a narrow moat suggest this isn't a runaway leader but a steady performer. With 25 analysts chiming in with a consensus buy rating and a median target of $100, the market's lukewarm sentiment stands in stark contrast to the robust ethical and financial profile Medtronic presents. Risks are inherent in any medtech investment, including regulatory hurdles and the ever-present need for innovation to stay competitive, yet Medtronic clears our ethical screen, aligning with our principles.
Analysis, not advice.
| Forward P/E | 14.9xfairly priced for its growth rate |
| Trailing P/E | 23.5xa premium valuation |
| EPS, trailing | 4.07 |
| EPS, forward | 6.41 |
| Revenue growth | +13.7%steady growth |
| Profit margin | 13.9%thin but positive margins |
| Return on equity | 10.6%a modest return on shareholder capital |
| FCF yield | 4.43% |
| Dividend yield | 3.69% |
| Debt to equity | 0.55moderate, manageable leverage |
| Current ratio | 2.07comfortably covers its short-term bills |
| Beta | 0.57steadier than the market |
| Short interest, float | 0.03% |
| 52-week range | 73.31 - 106.33 |
| Moat | NARROW |
| Market cap | $122.1B |
| Employees | 95,000 |
The risks · The things to watch: its business and earnings are exposed to Ireland and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeMDT trades on a US exchange (the company is based in Ireland). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-28
Markup $95.45
+0.0% Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (26 analysts) rates it buy, with a mean price target of $107.
2026-10-21
Markup · changed $95.45
+7.9% Entry 15
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.9% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (26 analysts) rates it buy, with a mean price target of $107.
2026-10-14
Distribution $88.48
-0.2% Entry 14
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (26 analysts) rates it buy, with a mean price target of $107.
2026-10-02
Distribution · changed $88.64
-4.1% Entry 13
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (26 analysts) rates it buy, with a mean price target of $107.
2026-09-17
Markup $92.39
+7.4% Entry 12
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.4% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (26 analysts) rates it buy, with a mean price target of $107.
2026-08-18
Markup $85.99
+0.0% Entry 11
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (26 analysts) rates it buy, with a mean price target of $107. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-16
Markup $85.99
+0.0% Entry 10
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (26 analysts) rates it buy, with a mean price target of $107. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-15
Markup $85.99
+0.0% Entry 9
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (26 analysts) rates it buy, with a mean price target of $107. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-14
Markup $85.99
+0.0% Entry 8
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (26 analysts) rates it buy, with a mean price target of $107. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-13
Markup $85.99
+0.0% Entry 7
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 8%. The street (26 analysts) rates it buy, with a mean price target of $107. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks Yahoo Finance · 2d ago
- Global Leadless Pacemakers Market Size, Share, and Industry Analysis - Global Forecast to 2036 | Market to Reach USD 4.87 Billion as Dual-Chamber Pacing and Asia-Pacific Expansion Drive 12.8% CAGR Yahoo Finance · 2d ago
- Pinnacle Food Group Limited Engages Strategic Advisor to Support M&A Initiatives Yahoo Finance · 2d ago
- Medtronic Quietly Raised Its Dividend Again. Is It a Buy for Income Investors? Yahoo Finance · 2d ago
- Overheard in Boston: Medtech CEOs talk rising costs, turbulent markets, cyberattacks Yahoo Finance · 3d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
SYKStryker Corporation
ABTAbbott Laboratories
BSXBoston Scientific
EWEdwards Lifesciences
DXCMDexcom
GEHCGE HealthCare
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-15 | Marinaro Michael | EVP, Pres MedSurg, Americas | S - Sale | 10,420 | $1,000,320 |
| 2026-10-15 | Martha Geoffrey | COB, CEO | S - Sale | 50,000 | $4,750,000 |
| 2026-04-27 | BLOMQUIST DENISE L | Officer | 1,508 | · | |
| 2026-04-27 | LEE JOON SUP | Director | 1,803 | · | |
| 2026-04-27 | NABEL ELIZABETH G | Director | 2,111 | · | |
| 2026-04-27 | GROETELAARS JOHN P | Director | 1,444 | · | |
| 2026-04-27 | LEWIS GREGORY P | Director | 2,111 | · | |
| 2026-04-27 | JELLISON WILLIAM R | Director | 1,444 | · | |
| 2026-04-27 | POWELL KENDALL J | Director | 2,111 | · | |
| 2026-04-27 | DONNELLY SCOTT C | Director | 2,111 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-05-27 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-05-15 | Ro Khanna | Democrat | buy | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $74.54 | +7.8% | · | $1,078 | +7.8% |
| 2 months | $87.21 | -7.9% | · | $922 | -7.9% |
| 3 months | $86.67 | -7.3% | $0.71 | $935 | -6.5% |
| 6 months | $98.22 | -18.2% | $1.42 | $833 | -16.7% |
| 1 year | $85.25 | -5.7% | $2.84 | $976 | -2.4% |
| 2 years | $77.95 | +3.1% | $5.64 | $1,103 | +10.3% |
| 3 years | $75.96 | +5.8% | $8.40 | $1,169 | +16.9% |
| 5 years | $106.25 | -24.4% | $13.64 | $885 | -11.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever MDT does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.